



(12) Translation of
european patent specification

(11) NO/EP 2164501 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/737 (2006.01)
A61P 11/00 (2006.01)
A61P 11/06 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.07.18
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.04.20
(86)	European Application Nr.	08748030.7
(86)	European Filing Date	2008.05.30
(87)	The European Application's Publication Date	2010.03.24
(30)	Priority	2007.05.31, AU, 2007902930 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
(73)	Proprietor	Paradigm Biopharmaceuticals Limited, Level 2 517 Flinders Lane, Melbourne, VIC, AU-Australia
(72)	Inventor	COOMBE, Deirdre, Roma, 10 Chiswick Street, Wembly Downs, Western Australia 6019, AU-Australia KETT, Warren, Charles, 25 Sachem Circle, West Lebanon, NH 03784, US-USA
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	SULPHATED XYLANS FOR TREATMENT OR PROPHYLAXIS OF RESPIRATORY DISEASES
------	-------	--

(56)	References Cited:	WO-A1-91/15216 WO-A1-99/06025 WO-A2-2006/000814 US-A1- 2003 109 491 US-A1- 2005 282 775 RAO N V ET AL: "SULFATED POLYSACCHARIDES PREVENT HUMAN LEUKOCYTE ELASTASE-INDUCED ACUTE LUNG INJURY AND EMPHYSEMA IN HAMSTERS" THE AMERICAN REVIEW OF RESPIRATORY DISEASE, AMERICAN THORACIC SOCIETY, US, vol. 142, no. 2, 1 August 1990 (1990-08-01), pages 407-412, XP001041125 ISSN: 0003-0805 ZENG DEWAN ET AL: "Heparin attenuates symptoms and mast cell degranulation induced by AMP nasal provocation" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 114, no. 2, August 2004 (2004-08), pages 316-320, XP002584378 ISSN: 0091-6749 SOUZA-FERNANDES ALBA B ET AL: "Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease." CRITICAL CARE (LONDON, ENGLAND) 2006 LNKD- PUBMED:17118216, vol. 10, no. 6, 2006, page 237, XP002584379 ISSN: 1466-609X WELLSTEIN A. ET AL.: 'Inhibition of fibroblast growth factors' BREAST CANCER RESEARCH AND TREATMENT vol. 38, 1996, pages 109 - 119, XP002129528 SCHUMACHER K.A. ET AL.: 'The Preventive Effect of a Low-Molecular Pentosan-Polysulphate on DAS-induced increase in Pulmonary Vascular Resistance caused by Platelet-Aggregation' DRUG RES. vol. 23, no. 3, 1973, pages 431 - 433, XP009134014 JOFFE S.: 'Drug Prevention of Postoperative Deep Vein Thrombosis' ARCH. SURG. vol. 111,
------	----------------------	---

January 1976, pages 37 - 40, XP009133964

TSUBURA E. ET AL.: 'Effects of Sulfated Polysaccharides on Blood-born Pulmonary Metastasis in Rats' GANN vol. 67, December 1976, pages 849 - 856, XP008126481

KAMITAKAHARA H.: 'Sulfated glycofuranans as inhibitors of melanoma lung metastasis' J.

WOOD SCI. vol. 48, 2002, pages 204 - 209, XP008126482

ANDREWS J.L.: 'The interaction of pentosan polysulfate (SP54) with human neutrophil elastase and connective tissue matrix components' CHEM.-BIOL. INTERACTIONS vol. 47, 1983, pages 157 - 173, XP008126483

CHIANG G. ET AL.: 'Pentosanpolysulphate (Elmiron) is a potent inhibitor of mast cell histamine secretion' ADV. EXP. MED. BIOL. vol. 539, no. 220, 2003, pages 713 - 729, XP009133960

OHYASHI HIROYUKI: "Neutrophil elastase inhibitors as treatment for COPD", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 11, no. 7, 1 July 2002 (2002-07-01), pages 965-980, XP009148446, ISSN: 1354-3784, DOI: 10.1517/13543784.11.7.965

J A NADEL ET AL: 'ROLE OF NEUTROPHIL ELASTASE IN HYPERSECRETION IN ASTHMA
ROLE OF NEUTROPHIL ELASTASE IN HYPERSECRETION IN ASTHMA' EUR RESPIR J, [Online] vol. 13, 01 January 1999, pages 190 - 196, XP055089501 Retrieved from the Internet: <URL:<http://erj.ersjournals.com/content/13/1/190.full.pdf#page=1&view=FitH>> [retrieved on 2013-11-21]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Farmasøytisk sammensetning omfattende en effektiv mengde av et sulfatert xylan, hvori det sulfaterte xylanet er pentosanpolysulfat (PPS), for anvendelse i
5 behandling eller profylakse av en inflammatorisk respiratorisk tilstand valgt fra listen bestående av astma, allergisk rhinitt og kronisk obstruktiv lungesykdom (COPD) hos et individ.
2. Den farmasøytiske sammensetningen ifølge krav 1, hvori individet er ett
10 menneske.
3. Den farmasøytiske sammensetningen ifølge krav 2, ytterligere omfattende et anti-inflammatorisk middel.
4. Den farmasøytiske sammensetningen ifølge krav 3, hvori det anti-
15 inflammatoriske middelet er et anti-histamin, en antagonist av G-CSF, M-CSF og/eller GM-CSF, en antagonist av IL-5, IL-4 eller IL-13, en antagonist av eotaksin-1 eller eotaksin-2 eller en antagonist av IL-8, MCP-1 eller MIP-1 α .
5. Anvendelse av et sulfatert xylan, hvori det sulfaterte xylanet er PPS, i
20 fremstilling av et medikament for behandling eller profylakse av en inflammatorisk respiratorisk tilstand valgt fra listen bestående av astma, allergisk rhinitt og kronisk obstruktiv lungesykdom (COPD) hos et individ.
6. Anvendelse ifølge et hvilket som helst av krav 5, hvori individet er et
25 menneske.
7. Anvendelse ifølge krav 6, ytterligere omfattende anvendelsen av et anti-
inflammatorisk middel.
30
8. Anvendelse ifølge krav 7, hvori det anti-inflammatoriske middelet er et anti-
histamin, en antagonist av G-CSF, M-CSF og/eller GM-CSF, en antagonist av IL-4
eller IL-5 eller IL-13, en antagonist av eotaksin-1 eller eotaksin-2 eller en
35 antagonist av IL-8 eller MCP-1 eller MIP-1 α .
9. Den farmasøytiske sammensetningen omfattende en effektiv mengde av PPS
og et anti-inflammatorisk middel valgt fra listen bestående av en antagonist av

G-CSF, M-CSF, GM-CSF, IL-4, IL-5, IL-13, eotaksin 1, eotaksin-2, MCP-1 og MIP-1 α for anvendelse i behandling av et individ med astma, allergisk rhinitt eller COPD.